Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients

Bone Marrow Transplantation

Volumn 50, Issue , 2015, Pages S72-S76

  Schlegel, P ^a   Feuchtinger, T ^a   Nitschke Gerard C ^a   Eva Seidel, U J ^a   Lang, A M ^a   Kyzirakos, C ^a   Teltschik, H M ^a   Ebinger, M ^a   Schumm, M ^a   Koscielniak, E ^b   Handgretinger, R ^a   Lang, P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b OLGAHOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DINUTUXIMAB; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MYCOPHENOLIC ACID; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; PREDNISONE; THIOTEPA; TOPOTECAN; TREOSULFAN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CELL MEDIATED CYTOTOXICITY; DISEASE SEVERITY; EFFECTOR CELL; EWING SARCOMA; EWING SARCOMA CELL LINE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LONG TERM SURVIVAL; LOW DRUG DOSE; MALE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; PATHOLOGY; PREVENTION AND CONTROL; SARCOMA, EWING;

ADOLESCENT; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SARCOMA, EWING;

EID: 84930420507     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.100     Document Type: Article

References (42)

1. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999; 17: 2796-2803.
2. Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463-3469.
3. Langler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood-a phase-II-study. Klin Padiatr 2002; 214: 153-156.
4. Ahn YO, Weigel B, Verneris MR. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res 2010; 16: 3819-3821.
5. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284-3291.
6. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
7. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al. Reducedintensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
8. Perez-Martinez A, de Prada Vicente I, Fernandez L, Gonzalez-Vicent M, Valentin J, Martin R et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol 2012; 40: 882-91 e1.
9. Parmar S, Ritchie DS. Allogeneic transplantation as anticancer immunotherapy. Curr Opin Immunol 2014; 27C: 38-45.
10. Thiel U, Koscielniak E, Blaeschke F, Grunewald TG, Badoglio M, Diaz MA et al. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer 2013; 109: 2523-2532.
11. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T et al. No improvement of survival with reduced-versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22: 1614-1621.
12. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
13. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A. Natural killer cell alloreactivity for leukemia therapy. J Immunother 2005; 28: 175-182.
14. Perez-Martinez A, Leung W, Munoz E, Iyengar R, Ramirez M, Vicario JL et al. KIRHLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009; 53: 120-124.
15. Shamamian P, Mancini M, Kawakami Y, Restifo NP, Rosenberg SA, Topalian SL. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunol Immunother 1994; 39: 73-83.
16. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005; 24: 4634-4644.
17. Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol 2005; 23: 242-244.
18. Smith KB, Ellis SA. Standardisation of a procedure for quantifying surface antigens by indirect immunofluorescence. J Immunol Methods 1999; 228: 29-36.
19. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand J Immunol 1991; 34: 697-712.
20. So EC, Sallin MA, Zhang X, Chan SL, Sahni L, Schulze DH et al. A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity. J Immunol Methods 2013; 394: 40-48.
21. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 1996; 193: 199-206.
22. Peper JK, Schuster H, Loffler MW, Schmid-Horch B, Rammensee HG, Stevanovic S. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods 2014; 405: 192-198.
23. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473-481.
24. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440.
25. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 2014; 258: 45-63.
26. Handgretinger R, Chen X, Pfeiffer M, Schumm M, Mueller I, Feuchtinger T et al. Cellular immune reconstitution after haploidentical transplantation in children. Biolo Blood Marrow Transplant 2008; 14: 59-65.
27. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
28. Liu KY, Chen YH, Liu DH, Xu LP, Huang XJ. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant 2008; 42: 535-539.
29. Schlegel P, Teltschik HM, Pfeiffer M, Handgretinger R, Schumm M, Koscielniak E et al. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract Res Clin Haematol 2011; 24: 443-452.
30. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D et al. Graftversus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31: 1530-1538.
31. Hosono A, Makimoto A, Kawai A, Takaue Y. Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors. Bone Marrow Transplant 2008; 41: 1067-1068.
32. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19: 106-117.
33. A delicate balance: tweaking IL-2 immunotherapy. Nat Med 2012; 18: 208-209.
34. Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014; 32: 1445-1452.
35. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A: 261-267.
36. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 2012; 106: 1123-1133.
37. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22: 3549-3557.
38. Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T et al. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer 2010; 10: 501.
39. Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A. Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol 2000; 51: 618-625.
40. Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009; 218: 222-231.
41. Pfeiffer MM, Schumm M, Muller I, Handgretinger R, Lang P. IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT. Leukemia 2012; 26: 2435-2439.
42. Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J et al. Preemptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013; 48: 433-438.